Anti-Sclerostin antibody inhibits internalization of Sclerostin and Sclerostin-mediated antagonism of Wnt/LRP6 signaling. [PDF]
PLoS ONE, 2013 Sclerosteosis is a rare high bone mass disease that is caused by inactivating mutations in the SOST gene. Its gene product, Sclerostin, is a key negative regulator of bone formation and might therefore serve as a target for the anabolic treatment of ...
Maarten van Dinther +10 more
doaj +8 more sources
Sclerostin promotes human dental pulp cells senescence [PDF]
PeerJ, 2018 Background Senescence-related impairment of proliferation and differentiation limits the use of dental pulp cells for tissue regeneration. Deletion of sclerostin improves the dentinogenesis regeneration, while its role in dental pulp senescence is ...
Yanjing Ou +3 more
doaj +4 more sources
Blocking interaction of sclerostin loop3 with osteoblastic LRP4 counteracts bone loss without increasing arterial stiffness during mechanical unloading [PDF]
Journal of Orthopaedic TranslationBackground: Mechanical unloading leads to bone loss and cardiovascular deconditioning, accompanied by elevated sclerostin expression. Genetic Sost knockout or pharmacologic sclerostin antibody treatment was reported to counteract bone loss during ...
Luyao Wang +26 more
doaj +2 more sources
Osteoblastic sclerostin loop3-LRP4 interaction required by sclerostin to inhibit bone formation [PDF]
Bone ResearchSclerostin negatively regulates bone formation. The marketed antibody against sclerostin loop2 promoted bone formation but may have caused severe cardiovascular events in clinical use.
Luyao Wang +25 more
doaj +2 more sources
Cardiovascular Safety of Anti-Sclerostin Therapy in Chronic Kidney Disease
Metabolites, 2021 The significance of sclerostin for bone and cardiovascular health in patients with chronic kidney disease (CKD) is complex and incompletely understood. Experimental evidence suggests that anti-sclerostin therapy shows diminished efficacy on bone in the ...
Daniel Cejka
doaj +2 more sources
Elevated sclerostin levels in cerebrospinal fluid are associated with cognitive impairment in the Alzheimer's disease continuum [PDF]
Alzheimer’s & Dementia: Diagnosis, Assessment & Disease MonitoringIntroduction Bone‐derived sclerostin impairs cognitive function in both patients with Alzheimer's disease (AD) and mouse models of AD. For the first time, we explored the correlation of sclerostin with neurocognitive domains in the AD continuum.
Patrizia Pignataro +12 more
doaj +2 more sources
Intracellular sclerostin promotes tumor progression and metastasis as a potential therapeutic target in triple-negative breast cancer [PDF]
Cell Reports MedicineSummary: Triple-negative breast cancer (TNBC) urgently requires promising therapeutic targets. This study identifies sclerostin, an osteocyte-derived secretory protein traditionally linked to bone homeostasis, as an unexpected intracellular oncogenic ...
Meiheng Sun +24 more
doaj +2 more sources
Kidney & Blood Pressure Research, 2021 Introduction: Sclerostin could enhance renal excretion of calcium (Ca) and phosphate (P). The association between sclerostin and magnesium (Mg) has not yet discovered.
Ching-Fang Wu +7 more
doaj +1 more source
B4GALNT3 regulates glycosylation of sclerostin and bone massResearch in context
EBioMedicine, 2023 Summary: Background: Global sclerostin inhibition reduces fracture risk efficiently but has been associated with cardiovascular side effects. The strongest genetic signal for circulating sclerostin is in the B4GALNT3 gene region, but the causal gene is ...
Sofia Movérare-Skrtic +15 more
doaj +1 more source
Sclerostin is upregulated in the early stage of chondrogenic differentiation, but not required in endochondral ossification in vitro. [PDF]
PLoS ONE, 2018 Sclerostin is a potent inhibitor of the canonical Wnt signaling pathway. Wnt signaling pathways have multiple roles in the regulation of cartilage development, growth, and maintenance.
Yasuteru Yamaguchi +4 more
doaj +1 more source